Table 3.

Summary of Five Cases Died Receiving Ceftazidime-Avibactam for Carbapenem-Resistant Pathogen Infections

Age	Sex	Comorbidity	Infection Source	Species	Carbapenemase	Therapy	Dosing	Duration (Days)	Microbiological Eradication	Comments
9 mo	F	HM	Pneumonia	Klebsiella pneumoniae	MBL	CAZ-AVI+ aztreonam	0.46g q8h	12	Yes	Admitted with fever and myelosuppression, died due to respiratory failure
5 y	F	HM	Bloodstream	Escherichia coli	MBL	CAZ-AVI+ aztreonam	1.25g q8h	18	Yes	Admitted with AML M5, had chemotherapy, died due to multiorgan failure
9 y	M	Trauma	Pneumonia Bloodstream	Klebsiella pneumoniae	Not tested	CAZ-AVI	2.5g q8h	4	No	Admitted with a traumatic brain injury and died due to progressive multiorgan failure
11 y	F	HM	Bloodstream	Escherichia coli	MBL	CAZ-AVI+ aztreonam	2.3g q8h	8	Not tested	Admitted with joint pain, rapid worsening with septic shock, died due to respiratory failure
16 y	M	HSCT	Bloodstream	Klebsiella pneumoniae	SBL	CAZ-AVI+ tigecycline	2.5g q8h	10	No	Developed polymicrobial infections and died due to septic shock and multiorgan failure

Abbreviations: AML, acute myeloid leukemia; CAZ-AVI, ceftazidime-avibactam; F, female; HM, hematologic malignancies; HSCT, hematopoietic stem cell transplant; M, male; mo, months; MBL, metallo-β-lactamases; SBL, serine β-lactamases; y, years.